Efficacy News and Research

RSS
Positive results from study comparing exenatide once weekly to BYETTA

Positive results from study comparing exenatide once weekly to BYETTA

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

OU lab completes studies on new type of training technique

OU lab completes studies on new type of training technique

INS cites FDA-approved Totect antidote for anthracycline extravasations

INS cites FDA-approved Totect antidote for anthracycline extravasations

Update on new clinical developments and other initiatives related to Ceplene

Update on new clinical developments and other initiatives related to Ceplene

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

SBi secures $30mm credit facility to fund business expansion

SBi secures $30mm credit facility to fund business expansion

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Vion Pharmaceuticals receives complete response letter related to its NDA for Onrigin injection

Vion Pharmaceuticals receives complete response letter related to its NDA for Onrigin injection

ZYPREXA RELPREVV approved by FDA

ZYPREXA RELPREVV approved by FDA

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Preclinical graft study supports Cytori’s proposed mechanism of action

Preclinical graft study supports Cytori’s proposed mechanism of action

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.